Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT05223361
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 120 participants
- Registry
-
NCT05223361
-
- Other papers using this trial's data
- Comparison of six percent hydroxyethyl starch 130/0.4 and ringer's lactate as priming solutions in patients undergoing isolated open heart valve surgery: A double-blind randomized controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Iran
- Registry status
- Completed
Technical summary
Registry record NCT05223361. Randomized; triple masking; primary purpose prevention. Start 2016-04 (actual); primary completion 2021-04-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery
- Condition
- Heart Valve Diseases
- Intervention (Drug)
- Six percent hydroxy ethyl starch 130/0.4
- Intervention (Drug)
- Ringer lactate
- Lead sponsor
- Rajaie Cardiovascular Medical and Research Center
- Collaborator
- Heart Valve Disease Research Center
Record details
- Record id
cardio:ct-nct05223361- Content hash
e41addd37914c294037cacd61f8eb3eecfc3d479f230418d9f104e03eeae0c44